Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Joyce M. van Dodewaard-de Jong; Saskia J. A. M. Santegoets; Peter M. van de Ven; Jurjen Versluis; Henk M. W. Verheul; Tanja D. de Gruijl; Winald R. Gerritsen; Alfons J. M. van den Eertwegh

doi:10.1080/2162402X.2015.1105431

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Joyce M. van Dodewaard-de Jong
, Saskia J. A. M. Santegoets
, Peter M. van de Ven
, Jurjen Versluis
, Henk M. W. Verheul
, Tanja D. de Gruijl
, Winald R. Gerritsen
, Alfons J. M. van den Eertwegh

Research output: Contribution to journal › Article › Academic › peer-review

11 Downloads (Pure)

Original language	English
Journal	Oncoimmunology
Volume	5
Issue number	4
DOIs	https://doi.org/10.1080/2162402X.2015.1105431
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer vaccines
chemotherapy
docetaxel
GVAX
immunotherapy
mitoxantrone
prostate cancer

Access to Document

10.1080/2162402X.2015.1105431

Improved-efficacy-of-mitoxantrone-in-patients-with-castration-resistant-prostate-cancer-after-vaccination-with-gm-csf-tr.pdfFinal published version, 987 KBLicence: Taverne

Cite this

van Dodewaard-de Jong, J. M., Santegoets, S. J. A. M., van de Ven, P. M., Versluis, J., Verheul, H. M. W., de Gruijl, T. D., Gerritsen, W. R., & van den Eertwegh, A. J. M. (2016). Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology, 5(4). https://doi.org/10.1080/2162402X.2015.1105431

@article{12cdef935deb485f97ffdec7b5608a76,

title = "Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells",

keywords = "Cancer vaccines, chemotherapy, docetaxel, GVAX, immunotherapy, mitoxantrone, prostate cancer",

author = "\{van Dodewaard-de Jong\}, \{Joyce M.\} and Santegoets, \{Saskia J. A. M.\} and \{van de Ven\}, \{Peter M.\} and Jurjen Versluis and Verheul, \{Henk M. W.\} and \{de Gruijl\}, \{Tanja D.\} and Gerritsen, \{Winald R.\} and \{van den Eertwegh\}, \{Alfons J. M.\}",

year = "2016",

doi = "10.1080/2162402X.2015.1105431",

language = "English",

volume = "5",

journal = "Oncoimmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

van Dodewaard-de Jong, JM, Santegoets, SJAM, van de Ven, PM, Versluis, J, Verheul, HMW, de Gruijl, TD, Gerritsen, WR & van den Eertwegh, AJM 2016, 'Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells', Oncoimmunology, vol. 5, no. 4. https://doi.org/10.1080/2162402X.2015.1105431

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. / van Dodewaard-de Jong, Joyce M.; Santegoets, Saskia J. A. M.; van de Ven, Peter M. et al.
In: Oncoimmunology, Vol. 5, No. 4, 2016.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

AU - van Dodewaard-de Jong, Joyce M.

AU - Santegoets, Saskia J. A. M.

AU - van de Ven, Peter M.

AU - Versluis, Jurjen

AU - Verheul, Henk M. W.

AU - de Gruijl, Tanja D.

AU - Gerritsen, Winald R.

AU - van den Eertwegh, Alfons J. M.

PY - 2016

Y1 - 2016

KW - Cancer vaccines

KW - chemotherapy

KW - docetaxel

KW - GVAX

KW - immunotherapy

KW - mitoxantrone

KW - prostate cancer

U2 - 10.1080/2162402X.2015.1105431

DO - 10.1080/2162402X.2015.1105431

M3 - Article

C2 - 27141390

SN - 2162-4011

VL - 5

JO - Oncoimmunology

JF - Oncoimmunology

IS - 4

ER -